InfoSigMap is tested to investigate the alterations affecting the transcriptome of the three aforementioned typical cancer problems: (i) colorectal cancer KRAS mutated vs. wild type;10 (ii) colon cancer metastatic vs. primary (same samples profiled with two platforms: RNA-seq and microarrays);11 (iii) tumor vs. normal in four tissues (lung,12 gastric,13 colon,14 cervix15), and (iv) breast cancer late vs. early stage (from two data sources: TCGA and METABRIC16). This evidence concerns the gene KRAS and breast cancer.